Representative Robert Bresnahan, Jr. (R-Pennsylvania) recently sold shares of Zoetis Inc. NYSE: ZTS. In a filing disclosed on March 27th, the Representative disclosed that they had sold between $1,001 and $15,000 in Zoetis stock on February 25th. The trade occurred in the Representative's "JP MORGAN BROKERAGE ACCOUNT" account.
Representative Robert Bresnahan, Jr. also recently made the following trade(s):
- Purchased $1,001 - $15,000 in shares of Intuit NASDAQ: INTU on 3/7/2025.
- Sold $1,001 - $15,000 in shares of Tesla NASDAQ: TSLA on 3/6/2025.
- Purchased $1,001 - $15,000 in shares of SEA NYSE: SE on 3/5/2025.
- Sold $1,001 - $15,000 in shares of Credo Technology Group NASDAQ: CRDO on 3/4/2025.
- Purchased $1,001 - $15,000 in shares of Meta Platforms NASDAQ: META on 3/4/2025.
- Purchased $1,001 - $15,000 in shares of Twilio NYSE: TWLO on 3/4/2025.
- Sold $15,001 - $50,000 in shares of Alibaba Group NYSE: BABA on 3/4/2025.
- Purchased $1,001 - $15,000 in shares of Zoom Video Communications NASDAQ: ZM on 3/4/2025.
- Purchased $1,001 - $15,000 in shares of Intel NASDAQ: INTC on 3/3/2025.
- Purchased $1,001 - $15,000 in shares of Snowflake NYSE: SNOW on 3/3/2025.
Zoetis Stock Performance
Shares of NYSE ZTS traded up $1.02 during mid-day trading on Wednesday, hitting $162.93. 876,927 shares of the company were exchanged, compared to its average volume of 2,974,920. The stock has a 50 day simple moving average of $166.26 and a 200-day simple moving average of $174.05. Zoetis Inc. has a 1-year low of $144.80 and a 1-year high of $200.33. The company has a quick ratio of 1.08, a current ratio of 1.75 and a debt-to-equity ratio of 1.09. The firm has a market cap of $72.96 billion, a price-to-earnings ratio of 29.79, a price-to-earnings-growth ratio of 2.78 and a beta of 0.94.
Zoetis (NYSE:ZTS - Get Free Report) last released its earnings results on Thursday, February 13th. The company reported $1.40 EPS for the quarter, topping the consensus estimate of $1.37 by $0.03. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. The company had revenue of $2.32 billion during the quarter, compared to analysts' expectations of $2.30 billion. On average, sell-side analysts forecast that Zoetis Inc. will post 6.07 EPS for the current fiscal year.
Zoetis Dividend Announcement
The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 3rd. Stockholders of record on Monday, April 21st will be paid a dividend of $0.50 per share. This represents a $2.00 annualized dividend and a dividend yield of 1.23%. The ex-dividend date is Monday, April 21st. Zoetis's dividend payout ratio (DPR) is presently 36.56%.
Institutional Trading of Zoetis
Hedge funds have recently bought and sold shares of the company. Howard Capital Management Group LLC grew its position in shares of Zoetis by 0.8% in the third quarter. Howard Capital Management Group LLC now owns 104,866 shares of the company's stock valued at $20,489,000 after purchasing an additional 883 shares during the period. Principal Financial Group Inc. boosted its stake in Zoetis by 17.3% in the 3rd quarter. Principal Financial Group Inc. now owns 2,377,403 shares of the company's stock worth $464,497,000 after buying an additional 351,372 shares during the last quarter. Larson Financial Group LLC grew its holdings in Zoetis by 14.8% in the 3rd quarter. Larson Financial Group LLC now owns 1,588 shares of the company's stock valued at $310,000 after buying an additional 205 shares during the period. Harvest Fund Management Co. Ltd increased its stake in shares of Zoetis by 237.3% during the 3rd quarter. Harvest Fund Management Co. Ltd now owns 2,159 shares of the company's stock valued at $422,000 after acquiring an additional 1,519 shares during the last quarter. Finally, D.A. Davidson & CO. lifted its holdings in shares of Zoetis by 4.3% during the 3rd quarter. D.A. Davidson & CO. now owns 25,979 shares of the company's stock worth $5,076,000 after acquiring an additional 1,062 shares during the period. Institutional investors and hedge funds own 92.80% of the company's stock.
Insider Transactions at Zoetis
In related news, Director Willie M. Reed sold 1,210 shares of Zoetis stock in a transaction on Tuesday, March 11th. The stock was sold at an average price of $166.14, for a total value of $201,029.40. Following the transaction, the director now owns 11,245 shares in the company, valued at approximately $1,868,244.30. This trade represents a 9.71 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Roxanne Lagano sold 326 shares of the business's stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $170.00, for a total value of $55,420.00. Following the sale, the executive vice president now directly owns 15,781 shares of the company's stock, valued at approximately $2,682,770. This trade represents a 2.02 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 1,862 shares of company stock worth $312,254 in the last three months. Company insiders own 0.16% of the company's stock.
Analyst Ratings Changes
A number of brokerages have recently issued reports on ZTS. UBS Group started coverage on Zoetis in a research note on Monday, December 9th. They set a "neutral" rating and a $196.00 target price for the company. Morgan Stanley dropped their price target on Zoetis from $243.00 to $238.00 and set an "overweight" rating for the company in a research report on Friday, February 14th. Piper Sandler boosted their price objective on shares of Zoetis from $200.00 to $205.00 and gave the stock an "overweight" rating in a research report on Thursday, February 27th. Barclays raised their target price on shares of Zoetis from $242.00 to $244.00 and gave the company an "overweight" rating in a report on Friday, February 14th. Finally, Stifel Nicolaus reduced their price target on shares of Zoetis from $210.00 to $180.00 and set a "buy" rating on the stock in a report on Tuesday, January 7th. One equities research analyst has rated the stock with a hold rating, ten have issued a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Buy" and an average target price of $215.90.
Read Our Latest Stock Analysis on Zoetis
About Representative Bresnahan
Rob Bresnahan Jr. (Republican Party) is a member of the U.S. House, representing Pennsylvania's 8th Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.
Bresnahan (Republican Party) is running for re-election to the U.S. House to represent Pennsylvania's 8th Congressional District. He declared candidacy for the 2026 election.
Rob Bresnahan Jr. was born in Kingston, Pennsylvania. He earned a B.S. in business administration, management and operations from the University of Scranton in 2012. His career experience includes working as the chief financial officer and CEO of a family business, an electrical contracting company.
About Zoetis
(
Get Free Report)
Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.
See Also
Before you consider Zoetis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zoetis wasn't on the list.
While Zoetis currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market volatility creates opportunity. Our analysts have pinpointed 10 stocks perfectly positioned for exceptional growth this spring, even amid economic uncertainty. Don't miss your chance to access this timely research and invest with confidence.
Get This Free Report
